Skip to main content
Glama

Arcgis Fairfield

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.6/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

The description goes well beyond the read-only/idempotent annotations by disclosing specific behaviors: ambiguous matches return `figi_candidates` rather than asserting, unresolved identifiers are explicitly listed, identifiers are source-labelled, and enrichment degrades gracefully if GLEIF/OpenFIGI are unavailable. This is exactly the kind of behavioral context an agent needs.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness3/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is front-loaded with usage examples and a clear purpose, and it is organized by supported types. However, it is quite long and contains some non-essential asides and marketing-style phrasing ('replaces 2-3 manual lookups'), so it is wordy rather than concise.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a tool with two parameters and no output schema, the description covers all critical context: accepted inputs, output semantics, ambiguity handling, unresolved identifiers, source provenance, and failure degradation for both entity types. Nothing essential is missing.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Even though the schema already covers both parameters, the description adds significant semantics: ISIN inputs resolve via GLEIF, non-equity instruments resolve via FIGI, drug names resolve through RxNorm, and exact-name-only guidance for bonds is reinforced. This meaningfully exceeds the schema's parameter descriptions.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description states a specific verb ('resolve') and resource ('a user-spoken NAME to canonical/official identifiers'), and frames the tool as the preliminary step for other tools that require IDs. It distinguishes itself from research/profile tools by focusing on ID lookup, and enumerates supported entity types.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

It gives explicit trigger conditions ('Use FIRST whenever you have a name but need an ID') and elaborates supported input forms and edge cases for companies and drugs. However, it does not explicitly name alternative sibling tools or state 'when not to use this tool', so it falls short of the strongest guidance.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Arcgis Fairfield toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.5/5.0
Disambiguation2/5

Many tools have overlapping purposes, such as ask_pipeworx, ask_pipeworx_grounded, deep_research, and also multiple Polymarket tools (bet_research, polymarket_edges, polymarket_arbitrage). Descriptions try to differentiate but the boundaries are unclear, causing confusion.

Naming Consistency2/5

Naming conventions are mixed: some use snake_case (ask_pipeworx, query_layer), some use descriptive phrases (entity_profile, recent_changes), and there is no consistent verb_noun pattern. The variety makes it hard to predict tool names.

Tool Count1/5

33 tools is far too many for a server named 'Arcgis Fairfield', as most tools are unrelated to GIS or Fairfield (e.g., npm dependency checks, prediction markets, AI visibility). The tool count severely mismatches the server's purported scope.

Completeness1/5

The server's stated purpose is ArcGIS Fairfield, but only 3 tools (layer_info, query_layer, search_datasets) relate to that domain. Critical GIS operations like updating features or managing services are missing, while the vast majority of tools are for other domains.

Resources